Date: September 13-15, 2021 Venue-The Marriott Marquis Times Square, New York- Virtual only access also available On September 13-15, 2021, the FinovateFall is being held at The Marriott Marquis Times Square, New York. Organizations, financial institutions, fintech industry leaders, and finance influencers are invited to attend the FinovateFall 2021, an event that can also be accessed virtually. The event will be attended by global influencers and thinkers of the finance arena who will share their valuable insights and strategies on the latest global trends. FinovateFall offers a robust platform for the fintech fraternity to establish connections and derive ideas to take their business to the next level. The pandemic has altered the financial landscape with things going digital in a big way. The FinovateFall will benefit fintech professionals and financial institutions alike. At this Fintech conference, attendees can participate in various discussions, attend seminars, and listen to keynotes from industry stalwarts. You could share your perspectives on varied financial topics with peers and other finance heads. Finovate is a global platform that is known to encourage start-ups, tech companies, financial enterprises, regulators, and investors across the globe. A global-level webinar that believes in bringing your enterprise to the center stage, attendees can be a part of live discussions, meetings, live demos given by both startups and established companies, and learn from the insights of experienced fintech professionals. As the situation has still not returned to normal in many parts of the world, Finovate is organizing a physical event that can also be digitally accessed by fintech enthusiasts worldwide. What to Expect In the live demo sessions, each company gets 7 minutes to display its business goals and aspirations on a power-packed main stage in complete transparency. This event gives companies and startups a great chance to showcase their talents amidst fintech heads who might notice their caliber. Attendees can engage with their mentors and find new connections to grow their business network. The FinovateFall is attended by professionals leading the fintech revolution and industry heads with years of experience that they will share in this 3-day global event of the financial technology industry. Connect with us at the FinovateFall to network and collaborate with the most influential people in the fintech sphere. To know more details about the event and the discounts available, please visit https://informaconnect.com/finovatefall/.

Date: September 16-17, 2021 Online Livestream Event – Locations will vary Dynamic Global Events (“DGE”) invites biopharma and medical device industry professionals to join them online September 16-17, 2021, for the 2nd Clinical Trial Agreements Conference. DGE’s first event was held online earlier this year and was focused greatly on the COVID-19 pandemic, the confidentiality of subject data, and the increased use of telemedicine, among other topics. The first event helped industry professionals determine what needed to be considered before entering into a clinical trial agreement. This conference features a distinguished speaking faculty ready to offer the strategies and best practices to guide professionals through the negotiation process toward a successful clinical trial agreement result. Featured speakers during the two-day conference on September 16-17 will include Jeff Odom, Manager, Global Clinical Trial Contracts, Trial Capabilities – Eli Lilly (NYSE: LLY); Donald Louis Joseph Campodonico, Clinical Trials Contracts Officer I – Stanford University School of Medicine; Tracie Carroll, Associate General Counsel – Turning Point Therapeutics (NASDAQ: TPTX); and many others. Each of these speakers will be covering a specific topic area including, but not limited to, the impact of new standard contractual clauses and GDPR, the role of CROs in a clinical trial contract process; the in-depth look at negotiations between sites and sponsors; telemedicine and the role it plays with remote trial agreements; and the global landscape for clinical trial agreements. The Scarritt Group Companies, a company that supports clinical trial solutions, is sponsoring the event. Some of the event partners for the 2nd Clinical Trial Agreements Conference include BioMed Wire, InvestorBrandNetwork, Pharma Marketing Network, MedTube, and many other industry-driven organizations. Online registration for the event is being held by RegFox and can be completed online through DGE’s conference website. The event carried an early bird special (prior to 8/20/2021) ticket price of $996, and standard/on-demand ticket pricing is $1,196. Registration and log-in for the event will take place on September 16, between 8:30 am and 9:00 am EST. The Chairperson’s opening remarks will begin promptly at 9:00 am. For more information, or to see a full list of keynote speakers and partners for the 2nd Clinical Trial Agreements Conference, please visit the event website. To purchase tickets and register for the event, visit https://ibn.fm/O7ryT

• Avricore Health recently announced that screening had begun at 15 select Shoppers Drug Mart Pharmacies
• The company intends to expand its rapid diagnostics to other parts of Canada, as well as the US, UK, and EU
• Avricore aims to use diagnostics to generate data that it can then use to make better decisions and create outcomes
• It hopes to be a tremendous contributor to the critical data pool that is going to make medicines cheaper, more effective, and get to patients quicker

When Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) signed a master agreement with Shoppers Drug Mart Inc., Canada’s leading pharmacy network, in June 2021, it intended to provide accessible, high-quality diagnostics with real-time data reporting. This, coupled with the support offered by the pharmacy chain, the company noted, would be a powerful combination in the battle against chronic disease, including diabetes and cardiovascular conditions, in Canada (https://ibn.fm/RR2a5) So far, this partnership has been fruitful. In an August 10 update, Avricore announced 15 select Shoppers Drug Mart pharmacies had received the HealthTab(TM) systems, thus heralding the onset of patient testing to those with known conditions associated with pre-diabetes or already identified as diabetic. The systems, which feature the HealthTab-integrated Afinion 2 analyzers by Abbott (NYSE: ABT), aim at offering diagnostic support and pharmacist-led consultation services (https://ibn.fm/hZU1J). Initially, the master agreement stipulated that only 11 Shoppers Drug Mart stores would receive the platform and offer screening services, but the figure has since been updated to 15 locations. This update appears to be in line with Avricore’s goals, given that the company intends to expand its rapid testing to more pharmacies and pharmacy brands across Canada. It is also looking to expand to the US, UK, and EU. Notably, though, diagnostics are only a cog in the company’s ever-rotating wheel. In a podcast interview with Paul Benwell & Associates, Avricore CEO Hector Bremner described the testing as a means to an end (https://ibn.fm/0tTQv). “One of the many things I’ve learned in Covid testing, in particular, is that buying tests or doing testing is not a strategy. The only reason you are testing is to get information. That information is what you are supposed to be focusing on,” Bremner stated. He noted that HealthTab is about obtaining data and using it to make better decisions and create outcomes. It is this data that Avricore also intends to capitalize on as part of its monetization plan, particularly through de-identification. The platform can be used by major drug makers who wish to screen patients with chronic conditions in decentralized clinical trials; these manufacturers would pay depending on the agreed-upon model. In cases where drugs are extremely particular about kidney and heart functions, drug makers can use HealthTab to get the efficacy of the drug right. “So, every time that person [a patient taking such drugs] comes in and picks up their prescription, they should be tested, and their biomarkers should be matched up against what their current prescription level is and that dosage modified. That’s another way a drug maker can have an ongoing program to pay to make sure that their patients are more effectively served,” Bremner explained. By working with a pharmacy network, Avricore also aims to provide contract research organizations (“CROs”) the desired level of engagement with patients. These CROs, which are companies that run clinical trials on behalf of drug makers, can also purchase the de-identified data for their predictive software programs. “We think in the long run, Avricore is going to be a tremendous contributor to that critical data pool that is going to make medicines cheaper, more effective, and get to patients quicker,” Bremner explained. Avricore is a pharmacy service innovator focused on revolutionizing point-of-care data reporting for better patient outcomes. Aiming to become a leading health data company globally, AVCR is utilizing its point-of-care technologies, packaged into HealthTab, within the community of pharmacies. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• Company’s nonprovisional patent application includes claims to compositions, methods to support certain elements of preclinical and research programs
• Two international patent applications will grant Cybin the right to file future national applications into treaty member jurisdictions
• Cybin portfolio consists of 14 patent filings, 50-plus proprietary molecules, 50-plus preclinical studies and 4 active drug programs

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, is moving forward to progress and strengthen its IP portfolio by filing three patents this month. After receiving an international search report of its May 2021 Patent Cooperation Treaty (“PCT”) application, Cybin filed a U.S. nonprovisional patent application claiming priority to the May 2021 PCT application (https://ibn.fm/MHCO7), and the company also filed two additional international patent applications, bringing the potential to obtain patent coverage in 153 countries (https://ibn.fm/mZ0BL). According to the company, the International Patent Searching (“IPC”) authority provided a written opinion in support of the novelty, inventive steps and industrial applicability to multiple claims within Cybin’s patent filing. As a result, the nonprovisional patent application includes claims to compositions and methods to support certain elements of the company’s preclinical and research programs. “Cybin’s portfolio now consists of 14 patent filings, 50-plus proprietary molecules, 50-plus preclinical studies, and 4 active drug programs targeting major depressive disorder, alcohol use disorder, anxiety and therapy-resistant psychiatric disorders,” said Cybin CEO Doug Drysdale. “We continue to progress our IP portfolio across novel molecules, delivery mechanisms, processes and protocols as we continue to find new and novel discoveries through our preclinical findings, thus expanding and strengthening IP.” The two international patent applications, governed by the PCT, will grant Cybin the right to file future national applications into treaty member jurisdictions, including important potential markets for the company. In addition, the PCTs cover a library of phenethylamine and derivative drug-development candidates and methods of use. One of Cybin’s PCT patent applications is in connection with a group of proprietary compounds identified by the company’s research data as being key for further evaluation toward selection as potential therapeutics. The other PCT application includes claims and disclosures toward several other proprietary novel psychedelic compounds, including compounds with positive research data, meeting the company’s internal research metrics. Cybin believes these applications will further strengthen its proprietary CYB005 program, which is targeting therapy-resistant psychiatric disorders, and will provide compositions for further evaluation in future research programs. Cybin is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Company is beginning to deliver vehicles on a grander scale
• IMC anticipates deliveries to individuals, fleets, dealers and government agencies during the second half of the year
• With each step forward, Imperium is seeing its dealer-candidate network of future dealers expand

DSG Global (OTCQB: DSGT) and its automotive division, Imperium Motor Corp. (“IMC”), are taking significant steps forward as they strengthen their position in the growing market for smart new-energy vehicles. Imperium is working with two partners, Skywell Auto and Jonway Automotive Group, to offer 26 EV models for sale at both DSGT California facilities: the Fairfield Experience Center and Palmdale Manufacturing Facility (https://ibn.fm/vESr7). “The company is finally in a position, with increasing production and inventory, regular shipments and proper lines of credit with the various manufacturers, to begin delivering vehicles on a grander scale,” said Imperium Motors CEO Rick Curtis. “The current backlog is being processed, and the company anticipates deliveries to individuals, fleets, dealers and government agencies during the second half of the year.” In addition to its partnerships with Skywell Auto and Jonway Automotive Group, Imperium has received approval in Europe for its ET5 SUV and is expecting homologation in the North American market to soon follow. The company is also ready to deliver its new Rumble Air SS to Canada and is anticipating major exposure from its upcoming automotive shows, including BusCon and the Los Angeles Auto Show, where the company plans on unveiling new models as well as displaying many of its 26 current models. New models expected to be available soon include the popular new Jonway e-FORCE Scooters, which are new on the floor at the Experience Center, and Skywell’s 12-meter EV city bus, which just arrived in Palmdale. Imperium also announced that its Terra trucks are in hand and are undergoing various upgrades and homologation testing. Finally, the division’s D-11 cargo vans and multi-passenger vans, as well as the new Jonway T01 coupes ,are on their way to the Experience Center. With each step forward, Imperium is seeing its dealer-candidate network of future dealers expand. An EV sales and marketing company, IMC is focused on offering a wide variety of affordable vehicles equipped for the North American market with emphasis on great design, a green mindset, and superior performance and functionality. Its line of vehicles will comprise high-speed, mid-speed, and low-speed electric vehicles, including cars, trucks, SUVs, vans, buses and scooters. DSG Global is an emerging global technology company with an array of interconnecting businesses in some of the fastest-growing market sectors. With roots in the golf industry, in which it specializes in fleet management with patented analytics, mobile touch-screen engagement and electric golf carts under the Vantage Tag Systems (“VTS”) brand, the company is moving quickly with road-ready electric vehicles for sale in the third quarter of 2021 through its Imperium Motor Company subsidiary. For more information, visit the company’s website www.DSGTGlobal.com. NOTE TO INVESTORS: The latest news and updates relating to DSGT are available in the company’s newsroom at https://ibn.fm/DSGT

• Blue and green hydrogen are the two types of hydrogen fuel types being examined for primary use – blue is less expensive but has the potential for higher greenhouse gas production, green hydrogen uses renewable energy sources like solar and wind power and creates a cleaner fuel
• Toyota Motor Corp. has manufactured one of the first hydrogen fuel cell-powered vehicles (Mirai), but there are only a handful of refilling stations available in Britain and three in Australia
• Global green ammonia market size is expected to record a CAGR growth rate of 54% from 2020 to 2025.
• When combusted correctly, carbon-free ammonia has the potential to produce little to no emissions in the form of a water vapor
• FuelPositive Corp. is at the forefront of producing carbon-free ammonia for the creation of alternative zero-emission fuel sources

With a commitment to clean energy solutions, FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) is getting the message out about the seriousness of global warming by deploying carbon-free ammonia as a step to help reduce carbon emissions. There is currently a growing interest worldwide in generating carbon-free or green ammonia and green hydrogen fuel to help reduce these emissions. Most of the environmental impacts of hydrogen are dependent on how it is manufactured, and most of the hydrogen produced for power is done so by using a methane source. Blue and green hydrogen are the two hydrogen fuel types currently being examined as primary fuel sources. Blue hydrogen is the cheaper low-carbon hydrogen fuel option, but reports have shown that it emits more greenhouse gases than originally thought. Green hydrogen uses renewable energy sources like solar and wind power to create cleaner hydrogen fuel (https://ibn.fm/fa3Bi). While green hydrogen is the cleanest of all the renewables, it has its problems. Hydrogen on its own is extremely difficult to store and transport. Hydrogen production is energy intensive while the end product is very volatile and requires extreme pressure conditions to store and transport. Additionally, hydrogen transportation raises various safety concerns, especially in the absence of an established distribution infrastructure. FuelPositive’s carbon-free ammonia is an ideal substitute because it provides all the benefits of hydrogen fuel but solves the problems that have been associated with it. The company’s solution is dramatically less expensive to manufacture than pure hydrogen by volume. Its carbon free ammonia system requires 30 percent less energy than conventional ammonia production, with zero carbon emissions. Moreover, FuelPositive’s ammonia stores 65 percent more hydrogen than pure hydrogen by volume and is easy and safer to store and transport via an existing infrastructure. In fact, FuelPositive’s carbon-free NH3 provides the most efficient and safest way to produce, store and transport hydrogen, making it the ideal enabler for the hydrogen economy. With the growing concern of greenhouse gas emissions, there is a higher emphasis worldwide on creating sustainable carbon-free ammonia, known as green ammonia. The global green ammonia market size is expected to record a CAGR growth rate of 54% from 2020 to 2025. The fuel source is considered to be 100% renewable (https://ibn.fm/Nti6j). FuelPositive is uniquely positioned to leverage this expanding market’s opportunities, with its proprietary patent-pending first-of-its-kind carbon-free ammonia technology. The company’s carbon-free ammonia will:

• Help eliminate carbon emissions in agriculture
• Replace fossil fuels used in transportation, including large engine vessels
• Provide affordable and convenient hydrogen for fuel cells
• Provide electricity and grid storage
• Fuel the shift to a hydrogen economy
• Produce carbon credits on a substantial level
• Reduce the need for massive ammonia processing facilities, pipelines and long-distance shipping

FuelPositive’s technology can revolutionize hydrogen production, transport and utilization, at a time when the entire world is looking for innovative hydrogen technologies and solutions. Recently, the Energy Department announced a hydrogen “moonshot” program to invest in new technologies. Additionally, car manufacturer Toyota Motor Corporation (NYSE: TM) has even been exploring the possibility of fueling vehicles with hydrogen with the Mirai model. Only available in certain markets, the car is priced around $100,000. There are currently only a handful of refilling stations in Britain and three in Australia, so purchasing it in another country would not make much sense. The argument is that electric cars will become obsolete, and replacing them with another fuel source, such as hydrogen, will become necessary, according to an article titled ‘Hit the Gas’ by Top Gear host and journalist Jeremy Clarkson. When used properly, carbon-free ammonia only produces discernable emissions in the form of water vapor. Some of these emissions are completely inert. With one of the most polluting industries in the world belonging to agriculture, the development of carbon-free ammonia and hydrogen energy sourcing will help to significantly reduce the impact that this industry has on global warming. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Psychedelics date back to ancient times, with records showing their use among the Aztecs as well as cultures in North Africa and Europe for medicinal and cultural purposes
• The prohibition era marked significant strides in psychedelics research, including the ultimate prohibition of the possession, sale and manufacture of psychedelics
• The 21st century has seen a surge in psychedelics research, a critical factor that has initiated a renaissance in this industry
• Tryp Therapeutics remains at the forefront of this renaissance with its commitment to identifying and developing clinical-stage compounds for diseases with high unmet medical needs, like Fibromyalgia and Eating Disorder

Since its inception, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has remained committed to identifying and developing clinical-stage compounds for diseases with high unmet medical needs. It seeks to achieve this through accelerated regulatory pathways, and its main program, Psilocybin-For-Neuropsychiatric Disorders (PFN(TM)) program, is a testament to that. With PFN, Tryp focuses on developing psilocybin-based drug therapies for the treatment of specific neuropsychiatric disorders. So far, psilocybin has shown various advantages over mainstream alternatives already in the market. These benefits include natural blood-brain barrier penetration, increased efficacy, enhanced safety and toxicity profiles and reduced risk of abuse and addiction (https://ibn.fm/JUoAz). Given what Tryp has achieved so far, it is easy to see the potential that psychedelics hold in the treatment of psychological ailments along with other medical conditions with high unmet needs. Additionally, it is easy for one to appreciate the strides that have been taken and the role that companies such as Tryp are making to demystify the usage of these substances for medical purposes. Historically, psilocybin has been used in many specific cultures, not just for medicinal purposes but also to reach an altered state of consciousness. There is evidence of the Aztecs consuming mushrooms and even individuals in the Americas using psychedelics in specific ceremonies. In North Africa and Europe, cave paintings that date back to 4000 BC show psilocybin, thus proving the usage of these substances in particular rituals and medicinal purposes (https://ibn.fm/3zyUF). Fast forward to the prohibition era, which saw great strides in psychedelics research and stringent measures from governments and the United Nations that would, ultimately, see a ban on the possession, sale, and manufacture of psychedelics. The late 19th and early 20th centuries saw Arthur Heffter isolate mescaline from the peyote cactus and Albert Hofmann synthesizing LSD, among other huge milestones. However, the late 20th century saw the UN declaring LSD, DMT, and MDMA as controlled substances. In the 21st century, the scientific community has proven the potential of psychedelics to rewire or repair circuits in the brain. In 2020, research conducted by scientists in Spain showed that DMT could stimulate the production of new brain cells. That same year, Santa Cruz decriminalized psychedelic substances, including peyote, ayahuasca, and psilocybin (https://ibn.fm/Nk3ta). Currently, Tryp continues to contribute to the ongoing conversation regarding the use of psychedelics in the field of medicine. Additionally, bringing light to psilocybin usage in chronic pain indications. With its three strategic initiatives- develop, protect and monetize- Tryp remains committed to utilizing FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to not only shorten the approval timelines but also lower the cost of development programs (https://ibn.fm/6I1oK). This is in a bid to bring psychedelic treatments closer to the people. It also seeks to grow an industry that has been dormant for decades for all the wrong reasons. The psychedelic medical market is still in its early days. There is still a lot that needs to be done. However, one thing that remains true is the industry’s vast potential to transform healthcare. It is projected that by 2027, the medicinal psychedelics market will be valued at $6.8 billion, up from $2 billion in 2019. Experts have even noted that it could eventually become a $100 billion market. Tryp Therapeutics is capitalizing on this potential and leading the accompanying transformation. By doing so, Tryp is stamping its position as a leader in the ongoing psychedelic renaissance. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• Radio frequency (“RF”) technology designer and developer AmpliTech Group is leveraging this year’s Nasdaq uplisting and Russell Microcap Index placement to increase its market visibility
• AmpliTech builds and markets communications technology products for the satellite communications, space, telecommunications (5G/6G) and military defense markets
• Markets analysts forecast continued growth over the next five years in the RF component sector, with a CAGR of 13 percent in the multi-billion-dollar sector
• AmpliTech reported a 2021 Q2 55% YOY revenue increase
• A recent follow-on order from an existing global defense and aerospace customer evidences AmpliTech’s growth potential as it continues to build revenues and strategically use its financial resources

The ever-present need for solutions that improve the speed and security of Internet-based technologies is exemplified in the rollout and evolution of 5G wireless communication capabilities worldwide. State-of-the-art RF signal component developer AmpliTech Group (NASDAQ: AMPG, AMPGW) has seen industry attention to its IP for satellite and 5G communications networks grow following its Nasdaq uplisting earlier this year and its more recent inclusion on the Russell Microcap Index in conjunction with the yearly reconstitution of the index, which took effect June 25. AmpliTech strengthened its financial standing with over $30M in funding obtained through recapitalization during the winter and spring months and recently celebrated receipt of a follow-on order for its technology from a long-standing customer in the global defense and aerospace sector. The company reported growth in its year-over-year and sequential quarterly revenues and gross profits when it released Q2 financial figures for the period ending June 30. The company also recently reported a Q2 2021 revenue of $1,024,410 signifying a 55% increase from Q2’20 revenue of $660,699. AmpliTech’s gross profits rose 52.5% to $344,623 in Q2’21 compared to $225,988 in Q2’20. Additionally, the company’s 2021 Q2 results showed record bookings and a record $2.45M backlog (defined as contractually obligated purchase orders with a deadline for delivery). “As the economy reopens in the wake of COVID-19, our target industries and customers are returning to more normal business and procurement patterns, creating a growing range of revenue opportunities for our Company,” President and CEO Fawad Maqbool stated (https://ibn.fm/H5zz6). “We are proud that the performance, quality and return on investment of our solutions continues to earn repeat business from global leaders.” AmpliTech is increasing its product development and marketing efforts to meet pent-up demand it has observed building up in the satellite communications, defense and space industries during the course of the COVID-19 pandemic, as well as for needs in other commercial applications. Analysts at market observer Mordor Intelligence recently forecast growth in the RF components market at a compound annual growth rate (“CAGR”) of 13 percent over the course of the next five years (https://ibn.fm/xwH9a), similar to the pre-pandemic outlook of Grand View Research, Inc., which predicted a 14 percent CAGR to 2025 for revenues of $45.05 billion globally (https://ibn.fm/Ks8Dn). “RF engineering is incorporated into almost everything helping to transmit or receiving a radio wave across the complete RF spectrum (3 kHz to 300 GHz) that includes cellular phones, radios, Bluetooth, and Wi-Fi technology. With the advent of the Internet of Things (‘IoT’) and even greater wireless connectivity, there will be increased demand for RF components,” Mordor’s report stated. For more information, visit the company’s website at www.AmpliTechInc.com. NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG Safe Harbor Statement This release contains statements that constitute forward-looking statements. These statements appear in several places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company’s ability to execute its business plan as anticipated; (ii) trends affecting the Company’s financial condition or results of operations; (iii) the Company’s growth strategy and operating strategy. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements because of various factors. Other risks are identified and described in more detail in the “Risk Factors” section of the Company’s filings with the SEC, all of which are available on our website. We undertake no obligation to update, and we do not have a policy of updating or revising, these forward-looking statements, except as required by applicable law.

• The presentation highlighted the company’s INM-088 cannabinol topical eye drop to treat glaucoma
• InMed’s IntegraSyn is being used to help the company develop synthetic bioidentical rare cannabinoids in the lab, as most are only found in trace amounts in cannabis plants
• In addition to INM-088 for glaucoma, the company is currently working on CBN-based INM-755 to treat a rare genetic skin disorder called epidermolysis bullosa and is awaiting the answer to Phase II trial applications in various countries

Dedicated to delivering new therapeutic alternatives as a treatment for conditions with a high unmet medical need, InMed Pharmaceuticals (NASDAQ: INM) is leading the way as a clinical-stage company developing treatment alternatives using rare pharmaceutical-grade cannabinoids. The company’s operations and programs, in particular its ocular program, were the focus of a presentation given by InMed’s President and CEO Eric A. Adams and Senior Vice President of Pre-Clinical Research and Development Dr. Eric Hsu at the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021 (https://ibn.fm/60sc6). In the presentation, Adams and Dr. Hsu gave an overview of InMed’s ocular program, consisting of INM-088, a topical eye drop under development for the treatment of glaucoma using cannabinol (“CBN”). This cannabinoid is showing promise for potential neuroprotection and the reduction of intraocular pressure within the eye. There are over 100 rare cannabinoids that are found in only trace amounts in cannabis. Together, these rare cannabinoids only make up about 1% of the plant’s total biomass – but they are not without their benefits. InMed is currently focused on one cannabinoid, CBN, to meet the unmet needs for medicinal therapeutics for various conditions. The preclinical studies on CBN have shown a promising safety profile and potential therapeutic benefits that exceed tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”). In addition to INM-088, InMed is currently developing INM-755, a CBN topical cream geared toward treating epidermolysis bullosa, a genetic skin disorder. INM-755 has been evaluated in two Phase I clinical trials of healthy volunteers to date. The Company has also filed Clinical Trial Applications in several countries as a part of Phase II clinical trials for the same indication. With the availability of rare cannabinoids in the cannabis plant, it is economically impractical for InMed to try and rely solely on the plant as a primary source of these cannabinoids. The Company is developing IntegraSyn, a cannabinoid synthesis manufacturing system, to create these rare cannabinoids in a laboratory setting. The cannabinoids developed in the laboratory setting are bioidentical to the compounds extracted from the natural source. InMed is also focused on the development of proprietary manufacturing technology to produce rare cannabinoids in the lab and already has a on file to acquire a leading cannabinoid manufacturer. In late June, InMed entered a non-binding Letter of Intent (“LOI”) to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacturing and commercialization of rare cannabinoids. BayMedica is a revenue-stage biotech company producing high-quality, regulatory compliant rare cannabinoids, including cannabichromene (“CBC”), and providing them as a B2B supplier to distributors and manufacturers. With a focus on rare cannabinoids and their development in a laboratory setting, InMed is strongly positioned for a prominent role on the U.S. cannabinoid market, a sector valued at $2.3 billion in 2019 and anticipated to grow at a CAGR of 20.4%, resulting in a revenue forecast of $16.4 billion in 2027 (https://ibn.fm/37qod). Much of this growth can be attributed to the increasing number of medical practitioners prescribing cannabinoids for health-related issues. For more information, visit the company’s website at www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

• Red White & Bloom Brands Inc. is set to release its Q2 2021 financial results on Monday, August 30, 2021
• The announcement will also be followed by an update on the company’s asset purchases, accompanying notes along with management discussion and analysis
• Q1 2021 saw outstanding performance for the company, with the CEO announcing intentions to finalize its revised asset purchase of the Michigan investee
• The August 30 announcement will give an update to this and more investment decisions for Q2 2021

On July 27, 2021, Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) announced its 2021 1st quarter (“Q1”) financial results (https://ibn.fm/5HQS5). Brad Rogers, the Chairman and Chief Executive Officer (“CEO”) of the company, referred to its performance at the time as “Another great quarter for the company.” When making the announcement, Mr. Rogers also noted that the company would be building on the momentum from Q1, given how much traction it had received for its brand. More so, he pointed out that the company’s priority would be working towards finalizing its revised asset purchase of the Michigan investee in a move to grow sales and revenue. On Monday, August 30, 2021, the company is set to announce its Q2 2021 financial results (https://ibn.fm/xrTmy). It will give an update on asset purchases and other managerial decisions made over that period, including the Michigan investee mentioned above. Red White & Bloom Brands Inc. is a pioneer in the cannabis and hemp-derived product lines. It is strategically positioning itself to be among the top three multi-state operators of these products within the American market. Based in Vancouver, the company is committed to expanding its market reach, a move that has seen investments and pending acquisitions in Michigan and Massachusetts, along with additional plans to enter Florida and California at scale. Red White & Bloom Brands Inc. is set to create the first-ever standardized cannabis facility in the United States, thereby ensuring the superior quality of its products. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF